



Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser

Sep 16 2025, 5:05 PM EDT

Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray

Sep 10 2025, 5:05 PM EDT

Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference

Sep 4 2025, 8:00 AM EDT

Stock Overview

Symbol	KNE
Exchange	TSXV
Market Cap	4.99m
Last Price	\$0.03
52-Week	\$0.025 - \$0.13

11/03/2025 05:36 PM EST

Investor Relations

Kane Biotech Inc.
T: 204-453-1301
ir@kanebiotech.com

Board of Directors

Philip Renaud

Board Chair

Dr. John Coleman

Director

Anne Greven

Director

Dr. Robert Huizinga

Interim Chief Executive Officer

Dr. David Kideckel

Director

Shameze Rampertab

Director

Kane Biotech Inc.

190-100 Innovation Drive
Winnipeg, MB R3T 6G2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.